These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 28533474)

  • 1. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Adelstein D; Vermorken JB
    Oral Oncol; 2018 Jan; 76():52-60. PubMed ID: 29290286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.
    Jacinto JK; Co J; Mejia MB; Regala EE
    Br J Radiol; 2017 Nov; 90(1079):20170442. PubMed ID: 29053029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
    Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
    Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
    Eswaran P; Azmi KS
    J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
    Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
    Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
    Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
    Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Adelstein D; Van Gestel D; Vermorken JB
    Front Oncol; 2019; 9():86. PubMed ID: 30847300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.
    Morse RT; Ganju RG; TenNapel MJ; Neupane P; Kakarala K; Shnayder Y; Chen AM; Lominska CE
    Head Neck; 2019 Aug; 41(8):2492-2499. PubMed ID: 30856297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
    Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.